JPWO2023085420A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023085420A5 JPWO2023085420A5 JP2023528706A JP2023528706A JPWO2023085420A5 JP WO2023085420 A5 JPWO2023085420 A5 JP WO2023085420A5 JP 2023528706 A JP2023528706 A JP 2023528706A JP 2023528706 A JP2023528706 A JP 2023528706A JP WO2023085420 A5 JPWO2023085420 A5 JP WO2023085420A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- hydroxyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 64
- 239000001257 hydrogen Substances 0.000 claims 64
- 150000002431 hydrogen Chemical class 0.000 claims 55
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- -1 nitro, hydroxyl Chemical group 0.000 claims 18
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 14
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 14
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 14
- 229910052794 bromium Inorganic materials 0.000 claims 14
- 229910052801 chlorine Inorganic materials 0.000 claims 14
- 239000000460 chlorine Substances 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 14
- 239000011737 fluorine Substances 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 229910052740 iodine Inorganic materials 0.000 claims 14
- 239000011630 iodine Substances 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 229940124245 Ferroptosis inhibitor Drugs 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004806 ferroptosis Effects 0.000 claims 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000012268 mitochondrial disease Diseases 0.000 claims 2
- 125000006609 n-nonyloxy group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000005975 2-phenylethyloxy group Chemical group 0.000 claims 1
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 1
- 206010062938 Mitochondrial hepatopathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000003683 cardiac damage Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000006443 lactic acidosis Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 206010030875 ophthalmoplegia Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021185384 | 2021-11-15 | ||
| JP2021185384 | 2021-11-15 | ||
| PCT/JP2022/042198 WO2023085420A1 (ja) | 2021-11-15 | 2022-11-14 | フェロトーシス阻害剤及びその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023085420A1 JPWO2023085420A1 (https=) | 2023-05-19 |
| JPWO2023085420A5 true JPWO2023085420A5 (https=) | 2023-10-04 |
| JP7360229B2 JP7360229B2 (ja) | 2023-10-12 |
Family
ID=86335916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528706A Active JP7360229B2 (ja) | 2021-11-15 | 2022-11-14 | フェロトーシス阻害剤及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12441734B2 (https=) |
| EP (1) | EP4431496A4 (https=) |
| JP (1) | JP7360229B2 (https=) |
| KR (1) | KR102760018B1 (https=) |
| CN (1) | CN118251379B (https=) |
| WO (1) | WO2023085420A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE489185C (de) | 1925-04-15 | 1930-01-14 | Chemische Fabriken Dr Joachim | Verfahren zur Darstellung von Apoverbindungen aus Alkaloiden der Morphinreihe |
| WO2007134485A1 (en) | 2006-05-22 | 2007-11-29 | Lotus Pharmaceutical Co., Ltd. | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
| CN101407520B (zh) * | 2008-11-28 | 2011-02-16 | 成都军区昆明总医院 | 阿朴菲类生物碱及其衍生物在制备抗真菌药物中的应用 |
| CN101966228B (zh) * | 2009-07-27 | 2012-02-22 | 中国科学院成都生物研究所 | 一种厚朴生物碱的用途 |
| BRPI1001988A2 (pt) | 2010-01-20 | 2012-05-22 | Luiz Francisco Pianowski | uso de pelo menos um composto isoquinolìnico de fórmula i, composição farmacêutica para tratar ou prevenir doenças neurodegenerativas e método para tratamento ou prevenção de doenças neurodegenerativas |
| WO2015015248A1 (en) | 2013-07-30 | 2015-02-05 | Debreceni Egyetem 67% | The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes |
| CN109804229B (zh) | 2016-08-15 | 2021-05-25 | 国立大学法人大阪大学 | 电磁波相位振幅生成装置、电磁波相位振幅生成方法以及存储有电磁波相位振幅生成程序的非临时记录介质 |
| JP6958860B2 (ja) * | 2017-11-07 | 2021-11-02 | 学校法人自治医科大学 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
| CN110772517B (zh) | 2019-12-02 | 2022-10-04 | 四川大学华西医院 | 波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 |
| CN112494491B (zh) * | 2020-12-14 | 2022-04-01 | 东北大学 | 克班宁在制备预防或治疗神经退行性疾病的药物中的用途 |
-
2022
- 2022-11-14 CN CN202280076182.3A patent/CN118251379B/zh active Active
- 2022-11-14 WO PCT/JP2022/042198 patent/WO2023085420A1/ja not_active Ceased
- 2022-11-14 KR KR1020247018238A patent/KR102760018B1/ko active Active
- 2022-11-14 JP JP2023528706A patent/JP7360229B2/ja active Active
- 2022-11-14 US US18/710,113 patent/US12441734B2/en active Active
- 2022-11-14 EP EP22892918.8A patent/EP4431496A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8993622B2 (en) | Antiviral compounds | |
| US9796664B2 (en) | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | |
| US7179817B2 (en) | Carboxylic acid derivatives and drugs containing the same as the active ingredient | |
| US20110118314A1 (en) | Piperidine analogs as glycogen synthase activators | |
| CN1711085A (zh) | 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 | |
| JP2022519131A5 (https=) | ||
| JP2011513367A5 (https=) | ||
| WO2018133670A1 (zh) | 丁苯酞-替米沙坦杂合物及其制备方法和用途 | |
| JP2020524178A (ja) | ファルネソイドｘ受容体および可溶性エポキシドヒドロラーゼの二重調節剤 | |
| JPWO2023085420A5 (https=) | ||
| US7939569B1 (en) | Aniline analogs as glycogen synthase activators | |
| JP2019536778A5 (https=) | ||
| JP4246997B2 (ja) | 糖尿病由来虚血性心疾患の治療及び／または予防剤 | |
| JP2009536967A5 (https=) | ||
| TW201305121A (zh) | 醯基苯衍生物 | |
| CN103096892B (zh) | 含有氨甲酰氧基芳基烷酰基芳基哌嗪化合物的药物组合物 | |
| JPH0530823B2 (https=) | ||
| CN103827111B (zh) | N-杂环取代酰胺衍生物 | |
| JP5253174B2 (ja) | Ｎ−フェニルオキサミド酸誘導体 | |
| JP2009504762A5 (https=) | ||
| KR102793464B1 (ko) | 신규한 hdac6 선택적 억제제 및 이의 용도 | |
| PT1341753E (pt) | ¿ciclo-hexil(alquil)-propanolaminas, sua preparação e composições farmacêuticas que as contêm¿ | |
| WO2024138317A1 (zh) | 一种甲状腺激素受体β激动剂化合物及其制备方法和应用 | |
| JP2009534310A5 (https=) | ||
| JP2002201171A (ja) | ウレアカルボン酸誘導体 |